Shots:
- The NMPA has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults
- Approval was based on data from the global P-III (RAPID) trial & a Chinese P-III (JX02002) study. JX02002 met its 1EP, showing etripamil’s superiority over PBO in converting PSVT to sinus rhythm within 30min.
- NMPA approval triggered a $2M milestone payment to Milestone Pharmaceuticals under its licensing agreement with Everest Medicines, which under the deal hold exclusive Greater China rights
Ref: Globenewswire | Image: Milestone | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
